Table 4.

Univariate and multivariate analysis for PFS and OS

Univariate analysisMultivariate analysis
HR (95% CI)P value (Log-Rank test)HR (95% CI)P value
PFS
 Agea2.25 (0.88–5.75)0.084.21 (1.42–12.50)0.009
 KPSb1.22 (0.48–3.08)0.67n.s.
 Chemotherapyc1.07 (0.39–2.98)0.89
 6q22 loss3.42 (1.36–8.62)0.0064.62 (1.52–14.01)0.006
 6p21.32 loss2.1 (0.79–5.42)0.13
 12q12-22 gain1.01 (0.39–2.63)0.98
CDKN2A hd2.99 (1.24–7.20)0.013.08 (1.13–8.39)0.02
MYD88 mut1.44 (0.61–3.40)0.41
TBL1XR1mut2.55 (0.82–7.90)0.09
OS
 Agea2.33 (0.77–7.01)0.134.26 (1.13–16.10)0.03
 KPSb1.15 (0.39–3.38)0.8n.s.
 Chemotherapyc1.15 (0.32–4?13)0.83
 6q22 loss3.78 (1.36–10.53)0.0064.45 (1.38–14.35)0.01
 6p21.32 loss1.43 (0.40–5.26)0.58
 12q12-22 gain1.48 (0.50–4.35)0.47
CDKN2A hd4.37 (1.47–12.95)0.0044.56 (1.35–15.30)0.01
MYD88 mut1.59 (0.56–4.43)0.38
TBL1XR1 mut2.60 (0.68–9.90)0.16

Variables included in multivariate analysis were: age, KPS, 6q22 loss, and CDKN2A hd.

Mut, mutation; Hd, homozygous deletion; n.s., nonsignificant.

  • aAge (<60 vs. > or = 60 years).

  • bKPS (<70 vs. > or = 70 years).

  • cChemotherapy (with vs. without high intravenous dose cytarabine).